Most Read

SNX281 is Stingthera’s small molecule agonist of the Stimulator of Interferon Genes (STING) protein. An anti-programmed death receptor-1 (anti-PD-1) therapy, Keytruda is a registered trademark of Merck &

Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies. Under the deal, Novartis gets the sole rights

Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics. As part of the collaboration, the companies will discover, develop, and

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Pfizer-BioNTech’s Covid-19 vaccine for children aged 5 to 11 years. The 10-µg vaccine doses

Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast

Pfizer and its partner BioNTech have announced that the US government has purchased additional paediatric doses of their Covid-19 vaccine, as it prepares for paediatric vaccinations. Under the

Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform. Koch Disruptive Technologies led the funding round

Takeda Pharmaceutical has exercised its option to acquire GammaDelta Therapeutics to accelerate development of allogeneic γδT cell therapies to address solid tumours. In 2017, the companies formed a

Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter’s drug candidates, anle138b and sery433, for neurodegenerative disease. Under the deal, Teva will have an